BC Innovations | May 10, 2018
Emerging Company Profile

Abac’s precision platform

Abac Therapeutics S.A. is taking a precision approach to treat bacterial infections that could avoid the development of drug resistance that plagues broad-spectrum antibiotics. The company’s PasNas platform uses phenotypic and in vitro assays to...
BioCentury | Feb 16, 2018

Quark gets specific

Abac Therapeutics S.A.’s targeted approach to antibiotic development led Quark Venture to join the company’s €16 million ($19.6 million) series A round, which will enable it to bring its lead program into the clinic. Pontifax...
Items per page:
1 - 2 of 2